Trial Profile
Saxagliptin and Atherosclerosis. A Possible Role for Saxagliptin in the Prevention of Atherosclerosis Beyond Glucose Metabolism.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Saxagliptin (Primary)
- Indications Atherosclerosis; Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- Acronyms SAXATH
- 16 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 21 Mar 2012 New trial record